Live Earnings Conference Call: Blueprint Medicines will host a live Q1 2025 earnings call on May 1, 2025 at 8:00AM ET. Follow this link to get details and listen to Blueprint Medicines' Q1 2025 earnings call when it goes live. Get details. Blueprint Medicines (BPMC) Competitors $89.50 +1.02 (+1.15%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPMC vs. SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, and ROIVShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Blueprint Medicines (NASDAQ:BPMC) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations. Does the MarketBeat Community favor BPMC or SMMT? Blueprint Medicines received 241 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 58.57% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55268.23% Underperform Votes25731.77% Summit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% Is BPMC or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Blueprint Medicines' return on equity of -77.49% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Summit Therapeutics N/A -85.42%-52.66% Do analysts recommend BPMC or SMMT? Blueprint Medicines currently has a consensus target price of $124.53, suggesting a potential upside of 39.14%. Summit Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 55.47%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.68Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in BPMC or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer BPMC or SMMT? In the previous week, Summit Therapeutics had 4 more articles in the media than Blueprint Medicines. MarketBeat recorded 25 mentions for Summit Therapeutics and 21 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.20 beat Summit Therapeutics' score of 0.70 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 14 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, BPMC or SMMT? Blueprint Medicines has higher revenue and earnings than Summit Therapeutics. Blueprint Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M11.24-$67.09M-$1.08-82.87Summit Therapeutics$700K25,418.35-$614.93M-$0.31-77.81 Which has more volatility and risk, BPMC or SMMT? Blueprint Medicines has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. SummaryBlueprint Medicines beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks. Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.72B$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-82.877.4422.4418.48Price / Sales11.24242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book19.166.516.774.25Net Income-$67.09M$143.21M$3.22B$248.23M7 Day Performance3.96%1.98%1.49%0.89%1 Month Performance4.14%6.89%4.00%3.53%1 Year Performance-5.65%-2.52%16.21%5.08% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines2.5608 of 5 stars$89.50+1.2%$124.53+39.1%-2.0%$5.72B$508.82M-82.87640Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6645 of 5 stars$25.22+2.5%$35.40+40.4%+513.7%$18.60B$700,000.00-90.07110Analyst ForecastGap DownTEVATeva Pharmaceutical Industries3.2638 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8812 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4452 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8436 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsASNDAscendis Pharma A/S2.3344 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Positive NewsMRNAModerna4.3426 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900VTRSViatris1.8348 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6786 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionNews CoverageROIVRoivant Sciences2.1639 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860 Related Companies and Tools Related Companies SMMT Competitors TEVA Competitors ITCI Competitors GMAB Competitors RDY Competitors ASND Competitors MRNA Competitors VTRS Competitors QGEN Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPMC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPMC Stock Free BPMC Stock Alerts